Halaven (Breast Cancer) – Analysis and Forecasts to 2020

Summary

GlobalData’s pharmaceuticals report, “Halaven (Breast cancer) - Analysis and Forecasts to 2020” provides Halaven sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2010-2020). The report also includes information on Breast Cancer market. This report is built using data and information sourced from GlobalData’s proprietary databases, primary and secondary research using Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.

Scope

- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Halaven including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Halaven including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecasts from 2010-2020 for Halaven in the seven major markets

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets

Keywords

Halaven, Breast Cancer, eribulin mesylate, Sales forecast, Microtubule Inhibitor(Mitotic Inhibitor), Phase III, Phase 3, Pipeline, Competitors to Xeloda, Afinitor and Ixempra, EISAI

Table Of Contents

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 4
2 Introduction 5
2.1 Breast Cancer Market 5
2.2 Epidemiology 5
2.3 Etiology and Risk Factors 7
2.3.1 Age and Gender 7
2.3.2 Genetic Inheritance 7
2.3.3 Hormone Replacement Therapy 7
2.3.4 Radiation 7
2.3.5 Obesity 7
2.3.6 Alcohol Consumption 7
2.3.7 Late Child Birth 7
2.3.8 Use of Birth Control Pills 7
2.4 GlobalData Report Guidance 8
3 Breast Cancer: Market Characterization 9
3.1 Breast Cancer Market 9
3.2 Breast Cancer Market Forecasts and CAGR 9
3.3 Drivers of Breast Cancer Market 10
3.3.1 Breast Cancer: Most Frequent Cancer in Women 10
3.3.2 Increasing Breast Cancer Incidence Rate 10
3.3.3 Decreasing Breast Cancer Mortality Rate 12
3.3.4 High Survival Rates of Breast Cancer 14
4 Staging of Breast Cancer: Introduction 15
4.1 Distribution of Patients by Stages 15
4.1.1 Stages 15
5 Predictive Biomarker in the Treatment of Breast Cancer 17
6 Treatment Options of Breast Cancer 19
6.1 Stage 0 Breast Cancer: Treatment Options 19
6.2 Early Stage Breast Cancer (Excluding Stage 0) 20
6.3 Metastatic Breast Cancer (MBC) 22
6.3.1 Endocrine treatment: Adjuvant, First Line and Second Line 22
6.3.2 Cytotoxic Chemotherapy 24
6.3.3 Management of Patients with HER-2 Positive Patients 26
7 Halaven 28
7.1 Introduction 28
7.2 Mechanism of Action 28
7.3 Clinical Studies 28
7.4 Approval History of Halaven 30
7.5 Factors Affecting Sales of Halaven 30
7.5.1 Low Efficacy 30
7.5.2 Increasing Competition from Targeted Therapy 30
7.5.3 NICE Rejection 30
7.6 Drug Evaluation 31
7.6.1 Drug Risk Benefit Score 31
7.6.2 Intensity of Competition 32
7.7 Sales Forecasts 32
7.7.1 Target Patient Pool of Halaven 32
7.7.2 Dosing 33
7.7.3 Market Penetration 33
7.7.4 Annual Cost of Therapy 33
7.7.5 Sales Projections of Halaven 34
8 Breast Cancer Market: Appendix 43
8.1 Market Definitions 43
8.2 List of Abberiviations 43
8.3 Research Methodology 43
8.3.1 Coverage 44
8.3.2 Secondary Research 44
8.3.3 Forecasting 44
8.3.4 Number of Patients Approved to take the Drug 45
8.3.5 Net Penetration of Drug 45
8.3.6 Net Annual Dosing 45
8.3.7 Annual Cost of Therapy 45
8.4 Drug Sales Estimates Model 45
8.5 Contact Us 46
8.6 Disclaimer 46
8.7 Sources 46

List of Tables

Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030 5
Table 2: Five-Year Relative Survival Rates, 2005, By Stages 14
Table 3: Summary of Best Objective Tumor Response in Phase 2 Study 29
Table 4: Approval History of Halaven 30
Table 5: Drug Risk Benefit Score, Halaven 31
Table 6: Annual Cost of Therapy, Halaven, 2011 33
Table 7: Halaven, Breast Cancer, Global,Sales Forecasts ($m), 2010-2020 34
Table 8: Halaven, Breast Cancer, The US, Sales Forecasts ($m), 2010-2020 35
Table 9: Halaven, Breast Cancer, The UK, Sales Forecasts ($m), 2011-2020 36
Table 10: Halaven, Breast Cancer, France, Sales Forecasts ($m), 2012-2020 37
Table 11: Halaven, Breast Cancer, Germany, Sales Forecasts ($m), 2011-2020 38
Table 12: Halaven, Breast Cancer, Italy, Sales Forecasts ($m), 2012-2020 39
Table 13: Halaven, Breast Cancer, Spain, Sales Forecasts ($m), 2011-2020 40
Table 14: Halaven, Breast Cancer, Japan, Sales Forecasts ($m), 2011-2020 41

List of Figures

Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010 6
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010-2020 9
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 10
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005 11
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030 11
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030 12
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005 12
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030 13
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030 13
Figure 10: Broad Classification of Breast Cancer, By Type 15
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS 15
Figure 12: Classification of Invasive Breast Cancer, By Stages 16
Figure 13: Classification of Invasive Breast Cancer, By Treatment 16
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer 17
Figure 15: Breast Cancer Intrinsic Sub Types used for deciding Treatment Options for MBC 18
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness 18
Figure 17: Treatment Options, DCIS Breast Cancer 19
Figure 18: Treatment Options, LCIS Breast Cancer 20
Figure 19: Treatment Options, Stages I, II and IIIA 20
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer) 21
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer) 21
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer) 22
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer 23
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC 23
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer 25
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer 26
Figure 27: Drug Model Diagram of Halaven 32
Figure 28: Halaven, Breast Cancer, Global,Sales Forecasts ($m), 2010-2020 34
Figure 29: Halaven, Breast Cancer, The US, Sales Forecasts ($m), 2010-2020 35
Figure 30: Halaven, Breast Cancer, The UK, Sales Forecasts ($m), 2011-2020 36
Figure 31: Halaven, Breast Cancer, France, Sales Forecasts ($m), 2012-2020 37
Figure 32: Halaven, Breast Cancer, Germany, Sales Forecasts ($m), 2011-2020 38
Figure 33: Halaven, Breast Cancer, Italy, Sales Forecasts ($m), 2012-2020 39
Figure 34: Halaven, Breast Cancer, Spain, Sales Forecasts ($m), 2011-2020 40
Figure 35: Halaven, Breast Cancer, Japan, Sales Forecasts ($m), 2011-2020 41
Figure 36: Halaven, Breast Cancer, Global, Sales Distribution (%), 2018 42
Figure 37: Patients Approved for the Drug 45

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

Multiple Sclerosis (MS) Drugs and Biologics : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

This BCC Research study offers an overview of the multiple sclerosis (MS) disease-modifying product market, including regulatory issues accompanied by detailed analyses and forecasts by product. Its main ...

Sleep Aids : Technologies and Global Markets

Sleep Aids : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

Research on the working of the human brain in relation to sleep is a fairly new area, with many new and novel theories. The discovery of new mechanisms and chemicals in the brain has provided expanding ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.